Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Teucrium Wheat Fund — how do they compare? Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B), while Teucrium Wheat Fund trades at $26.26. Which is the better fit depends on your goals.
| VRTX | WEAT | |
|---|---|---|
Market Cap | $134.06B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $557.96 | $28.00 |
52-Week Low | $376.62 | $19.88 |
Enterprise Value | $128.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
WEAT, a US-listed wheat ETF, trades at $26.96, up 1.77% today, with a bullish technical signal from moving averages and ADX indicating strong trend momentum. Recent performance shows a 9.9% gain over the past month, driven by inflation concerns and commodity strength. Key support and resistance cluster around $27, suggesting a pivotal price zone.
Outlook remains positive due to inflation hedging demand, but risks include commodity price volatility and Federal Reserve policy shifts. The ETF lacks traditional fundamental metrics like P/E or revenue, relying on wheat futures performance. Investors should weigh macroeconomic trends against potential pullbacks in agricultural markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
